Skip to Main content Skip to Navigation
Journal articles

Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.

Abstract : Hormone therapy (HT) increases venous thromboembolism (VTE) risk among postmenopausal women. Data on the influence of steroids receptors polymorphisms on this association remain scarce. Since progesterone receptor (hPR) is expressed in human veins and specific progestogens increase VTE risk, we investigated the impact of the functional +331G/A hPR polymorphism on the association of VTE with HT. Using the data of the ESTHER study, we showed that ORs for VTE in current users of progesterone or progestins were not significantly different by hPR+331G/A genotype status. hPR polymorphism appears not to have a significant effect on VTE risk related to HT.
Complete list of metadatas

Cited literature [8 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01142841
Contributor : Pascale Sztajnbok <>
Submitted on : Thursday, April 16, 2015 - 10:03:47 AM
Last modification on : Wednesday, September 16, 2020 - 4:58:45 PM
Long-term archiving on: : Monday, September 14, 2015 - 9:36:22 AM

File

Bouaziz_Maturitas_2009.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Elodie Bouaziz, Marianne Canonico, Céline Verstuyft, Laure Carcaillon, Frédéric Martin, et al.. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.. Maturitas, Elsevier, 2009, 64 (2), pp.136-8. ⟨10.1016/j.maturitas.2009.08.013⟩. ⟨inserm-01142841⟩

Share

Metrics

Record views

256

Files downloads

327